A First-in-Human Phase I Clinical Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-Activating Protein in Patients with Metastatic Breast Cancer

被引：0

作者：

Yadav, Siddhartha ^{[1
]}

Iankov, Ianko ^{[2
]}

Viker, Kim ^{[2
]}

Haddad, Tufia ^{[1
]}

Giridhar, Karthik V. ^{[1
]}

Leon-Ferre, Roberto ^{[1
]}

Goetz, Matthew P. ^{[1
]}

Suman, Vera J. ^{[3
]}

Galanis, Evanthia ^{[1
]}

机构：

[1] Mayo Clin, Dept Oncol, Rochester, MN USA

[2] Mayo Clin, Dept Mol Med, Rochester, MN USA

[3] Mayo Clin, Dept Quantitat Hlth Sci, Rochester, MN USA

来源：

MOLECULAR THERAPY | 2023年 / 31卷 / 04期

关键词：

D O I：

暂无

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

294

引用

页码：156 / 156

页数：1

共 39 条

[31] First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and paclitaxel (P) in AMHRII-expressing advanced/metastatic gynecological cancer patients (pts)
Leary, Alexandra
Awada, Ahmad
Delord, Jean-Pierre
Floquet, Anne
Ray-Coquard, Isabelle Laure
Abdeddaim, Cyril
Fabbro, Michel
Kalbacher, Elsa
Vergote, Ignace
Banerjee, Susana N.
Frenois, Francois-Xavier
Noel, Gregory
Lantz, Olivier
Cassard, Lydie
Coste, Agnes
Villard, Marine
Lemee, Fanny
Tabah-Fisch, Isabelle Marie
Le Tourneau, Christophe
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] A phase I trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer (MBC)
Jhaveri, K.
Teplinsky, E.
Chandarlapaty, S.
Solit, D.
Cadoo, K.
Speyer, J.
D'Andrea, G.
Adams, S.
Patil, S.
Haque, S.
Friedman, K.
Neville, D.
Esteva, F.
Hudis, C.
Modi, S.
CANCER RESEARCH, 2016, 76
[33] Translational insights from a phase 1, first-in-human (FIH) clinical trial of the anti-HER2 CAR macrophage CT-0508 in participants with HER2 positive metastatic breast cancer and other HER2 overexpressing solid tumors
Abdou, Yara
Mortimer, Joanne
Pohlmann, Paula
Johnson, Melissa
Maziarz, Richard
Specht, Jennifer M.
Dees, Claire
Ueno, Naoto
Yuan, Yuan
Angelos, Mathew
Gill, Saar
Shestova, Olga
Serody, Jonathon
Priceman, Saul
Qureshi, Rehman
Sonawane, Poonam
Pierini, Stefano
Oliveira-Nunes, Maria Cecilia
Cushing, Daniel
Klichinsky, Michael
Condamine, Thomas
Swaby, Ramona
Reiss, Kim
CANCER RESEARCH, 2024, 84 (09)
[34] Myeloid progenitor cell proliferation and mobilization effects of BB10010, a genetically engineered variant of human macrophage inflammatory protein-1α, in a phase I clinical trial in patients with relapsed/refractory breast cancer
Broxmeyer, HE
Orazi, A
Hague, NL
Sledge, GW
Rasmussen, H
Gordon, MS
BLOOD CELLS MOLECULES AND DISEASES, 1998, 24 (02) : 14 - 30
[35] First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
Pham, Toan
Pereira, Lloyd
Roth, Sara
Galletta, Laura
Link, Emma
Akhurst, Tim
Ben Solomon
Michael, Michael
Darcy, Phillip
Sampurno, Shienny
Heriot, Alexander
Ramsay, Robert
Desai, Jayesh
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2019, 16
[36] Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial
Krop, Ian E.
Masuda, Norikazu
Mukohara, Toru
Takahashi, Shunji
Nakayama, Takahiro
Inoue, Kenichi
Iwata, Hiroji
Yamamoto, Yutaka
Alvarez, Ricardo H.
Toyama, Tatsuya
Takahashi, Masato
Osaki, Akihiko
Saji, Shigehira
Sagara, Yasuaki
O'Shaughnessy, Joyce
Ohwada, Shoichi
Koyama, Kumiko
Inoue, Tatsuya
Li, Li
Patel, Parul
Mostillo, Joseph
Tanaka, Yoshimi
Sternberg, David W.
Sellami, Dalila
Yonemori, Kan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5550 - +
[37] First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).
Floudas, Charalampos S.
Strauss, Julius
Allen, Clint
London, Nyall R.
Donahue, Renee Nicole
Jochems, Caroline
Steinberg, Seth M.
Cordes, Lisa M.
McMahon, Sheri
Marte, Jenn
Sater, Houssein Abdul
Redman, Jason
Karzai, Fatima
Bilusic, Marijo
Madan, Ravi Amrit
Brough, Douglas E.
Lankford, Amy
Schlom, Jeffrey
Gulley, James L.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[38] A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer
Ciruelos, Eva
Apellaniz-Ruiz, Maria
Cantos, Blanca
Martinez-Janez, Noelia
Bueno-Muino, Coralia
Echarri, Maria-Jose
Enrech, Santos
Guerra, Juan-Antonio
Manso, Luis
Pascual, Tomas
Dominguez, Cristina
Gonzalo, Juan-Francisco
Sanz, Juan-Luis
Rodriguez-Antona, Cristina
Sepulveda, Juan-Manuel
ONCOLOGIST, 2019, 24 (11): : E1024 - E1033
[39] First-in-human phase 1A study of RGT-419B, a next generation CDK4 inhibitor, in patients (pts) with hormone receptor positive (HR+) HER2advanced/metastatic breast cancer (ABC) who progressed on prior CDK4/6 inhibitors (CDK4/6i)
Wander, Seth
Valacer, Dave
Zuniga, Richard
Yeckes-Rodin, Heather
Perkins, Christopher
Ge, Lisa
Yao, Lili
Lin, Jing
Begley, Dawn
Sun, Feifei
Zheng, Andie
Han, Jing
Xie, Zhi
Bardia, Aditya
Kalinsky, Kevin
CANCER RESEARCH, 2024, 84 (09)

← 1 2 3 4 →